Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:CLVR NASDAQ:CMRA NASDAQ:EVLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00$0.00▼$0.00$1K-1.06780 shs350 shsCLVRClever Leaves$0.00$0.00▼$0.50$1K4212.865,336 shs13 shsCMRAComera Life Sciences$0.00$0.00▼$0.00$3K1.11,475 shsN/AEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$6K0.612,879 shs30 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%0.00%+50.00%-94.00%CLVRClever Leaves0.00%0.00%+33.33%+300.00%+300.00%CMRAComera Life Sciences0.00%0.00%0.00%0.00%0.00%EVLOEvelo Biosciences0.00%+150.00%+150.00%+25.00%-16.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00$0.00▼$0.00$1K-1.06780 shs350 shsCLVRClever Leaves$0.00$0.00▼$0.50$1K4212.865,336 shs13 shsCMRAComera Life Sciences$0.00$0.00▼$0.00$3K1.11,475 shsN/AEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$6K0.612,879 shs30 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%0.00%+50.00%-94.00%CLVRClever Leaves0.00%0.00%+33.33%+300.00%+300.00%CMRAComera Life Sciences0.00%0.00%0.00%0.00%0.00%EVLOEvelo Biosciences0.00%+150.00%+150.00%+25.00%-16.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ACLVRClever Leaves 0.00N/AN/AN/ACMRAComera Life Sciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00CMRAComera Life Sciences$1.00M0.00N/AN/AN/ANaNEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/AN/AN/AN/AN/AN/AN/A5/13/2026 (Estimated)CLVRClever Leaves-$17.90M-$12.36N/AN/AN/AN/AN/AN/A5/15/2026 (Estimated)CMRAComera Life Sciences-$18M-$0.31N/AN/AN/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53M-$8.81N/AN/AN/AN/AN/AN/A5/14/2026 (Estimated)Latest CALA, CMRA, EVLO, and CLVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026N/ACLVRClever Leaves-$10.95N/AN/AN/A$4.05 millionN/A5/14/2026N/AEVLOEvelo Biosciences-$10.40N/AN/AN/AN/AN/A5/13/2026N/ACALACalithera Biosciences-$4.8020N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ACLVRClever Leaves6.92%CMRAComera Life SciencesN/AEVLOEvelo Biosciences0.31%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%CLVRClever Leaves8.20%CMRAComera Life Sciences8.90%EVLOEvelo Biosciences1.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences603.86 million4.55 millionNot OptionableCLVRClever Leaves5601.76 million1.61 millionNo DataCMRAComera Life Sciences230.74 million28.00 millionNot OptionableEVLOEvelo Biosciences12018.84 million18.79 millionNo DataCALA, CMRA, EVLO, and CLVR HeadlinesRecent News About These CompaniesEvelo BiosciencesApril 5, 2026 | fool.comStock Traders Buy High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)December 25, 2025 | defenseworld.netDEvelo's Compass E-Trike Has Comfort, Range, and Even Power; Priced Decently Well, TooApril 17, 2025 | autoevolution.comAEvelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comEvelo Biosciences, Inc. (EVLO)August 24, 2024 | nz.finance.yahoo.comEvelo Biosciences Stock (OTC:EVLO), Short Interest ReportFebruary 22, 2024 | benzinga.comEvelo Biosciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of ListingDecember 6, 2023 | cbonds.comCEvelo Biosciences, a microbiome company launched by Flagship, shuts downNovember 24, 2023 | msn.comEvelo Bio Shutdown Follows a Series of Microbiome Therapy Trial FailuresNovember 23, 2023 | medcitynews.comMFlagship-backed startup Evelo, behind failed eczema drug, to dissolveNovember 22, 2023 | bizjournals.comEvelo’s voyage ends, as Flagship-founded biotech finds dissolution is only viable optionNovember 22, 2023 | fiercebiotech.comFFMR LLC Reduces Stake in Evelo Biosciences IncNovember 14, 2023 | finance.yahoo.comEvelo Biosciences Inc EVLONovember 10, 2023 | morningstar.comMPresident & CEO GILL SIMBA sale 1,996 shares of Evelo Biosciences Inc [EVLO]November 3, 2023 | knoxdaily.comKQ3 2023 Horizon Technology Finance Corp Earnings CallNovember 2, 2023 | finance.yahoo.comHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comEvelo Biosciences (EVLO) Price Target Increased by 53.85% to 10.20November 1, 2023 | msn.comEVLO shares expected to outperform in the next 12 monthsOctober 26, 2023 | knoxdaily.comKMedia Sentiment Over TimeCALA, CMRA, EVLO, and CLVR Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0003 0.00 (0.00%) As of 12:26 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Clever Leaves NASDAQ:CLVRClever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Comera Life Sciences NASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Evelo Biosciences NASDAQ:EVLO$0.0003 0.00 (0.00%) As of 05/4/2026Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
